AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

SUPN · NASDAQ · Drug Manufacturers - Specialty & Generic

Supernus Pharmaceuticals (SUPN)

Develops CNS medicines spanning ADHD, Parkinson’s disease, postpartum depression, and epilepsy.

$43.75

After hours−0.04 (−0.09%)

At close$43.79(+2.36%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	154	164	144	168	176	174	150	165	192	212	208	219
Cost of revenue	20	20	16	18	18	26	16	17	19	23	23	34
Gross profit	134	145	127	150	158	148	134	149	173	189	184	185
	126	146	130	128	117	127	144	136	233	175	193	243
Research & development	23	23	25	26	29	29	27	22	29	28	39	29
	83	81	87	86	70	79	90	94	180	122	125	134
Selling & marketing	57	55	60	59	54	55	63	65	77	83	0	93
General & administrative	26	26	27	27	15	25	27	28	103	39	0	41
Other expenses	21	41	19	16	18	19	27	21	24	25	28	80
Operating income	8	−1	−3	23	41	21	−10	12	−60	14	−7	−58
	2	2	3	4	4	5	4	5	2	−16	1	0
Interest income	2	2	3	4	4	5	4	5	2	2	2	3
Interest expense	0	0	0	0	0	0	0	0	0	0	0	2
Other non-operating income	−2	−2	1	4	−4	−5	−8	−5	−2	12	−1	−3
Income before tax	10	1	0	26	45	26	−6	17	−58	−2	−6	−58
Income tax expense	26	0	0	6	6	11	6	−6	−13	2	−4	1
Net income from continuing operations	−16	1	0	20	38	15	−12	22	−45	−4	−2	−58
Net income	−16	1	0	20	38	15	−12	22	−45	−4	−2	−58
EPS, basic	−$0.29	$0.02	$0.00	$0.36	$0.70	$0.28	−$0.21	$0.40	−$0.80	−$0.07	−$0.04	−$1.01
EPS, diluted	−$0.29	$0.02	$0.00	$0.36	$0.69	$0.27	−$0.21	$0.40	−$0.80	−$0.07	−$0.04	−$1.01
Weighted average shares, basic	55	55	55	55	55	55	56	56	56	57	58	58
Weighted average shares, diluted	55	55	56	56	56	56	56	57	57	57	58	58
EBITDA	32	23	17	39	65	45	18	38	−33	27	20	−30
Depreciation & amortization	22	22	21	21	20	19	20	21	25	25	26	26
EBIT	10	1	−4	18	45	26	−3	17	−58	2	−6	−55